(NASDAQ:ASND),
– Q2 2025 revenue of EUR103.0 million for YORVIPATH(R) and EUR50.7 million for SKYTROFA(R)
– TransCon(R) CNP (navepegritide) NDA under Priority Review for the treatment of children with achondroplasia with PDUFA date of November 30, 2025
– SKYTROFA(R) (lonapegsomatropin-tcgd) approved in the U.S. for treatment of adults with growth hormone deficiency; first of many planned label expansions
– Week 26 Interim Results for COACH trial highlight the unique portfolio of once-weekly TransCon CNP and once-weekly TransCon hGH, with complementary modes of action, to potentially further transform the treatment landscape for growth disorders and physical functioning
-Conference call today at 4:30 pm ET
COPENHAGEN, Aug. 07, 2025 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the second quarter ended June 30, 2025, and provided a business update.
“With the robust global uptake of YORVIPATH and with TransCon CNP under U.S. FDA priority review, Ascendis is on the verge of bringing our third high-value medicine to patients and substantially transforming our financial profile,” said Jan Mikkelsen, Ascendis Pharma's President and Chief Executive Officer. “We expect our engine for future innovation to drive continued momentum as we aim to address unmet medical need in endocrine rare diseases and other large indications for years to come on our path to fulfilling Vision 2030.”
Select Highlights & Anticipated 2025 Milestones
- TransCon PTH:
(palopegteriparatide, marketed as YORVIPATH)- YORVIPATH revenue for the second quarter of 2025 totaled EUR103.0 million, including a negative foreign currency impact of EUR5.8 million compared to the previous quarter.
- Continued uptake from YORVIPATH in the U.S., with around 3,100 unique patient enrollments and more than 1,500 prescribing health care providers as of June 30, 2025.
- Outside the U.S., YORVIPATH generated revenue from more than 30 countries.
- Initiated PaTHway60, a single-arm safety and efficacy trial in patients to support U.S. label expansion to enable titration up to 60 ug dose.
- Recent presentations at medical conferences in Europe and the U.S. of TransCon PTH data out to four years of treatment demonstrate that preserving the same mode of action and providing active PTH within the physiological range for 24 hours per day comparable to endogenous PTH can normalize key elements such as calcium, phosphate, kidney function, bone turnover, and quality of life.
- TransCon hGH:
(lonapegsomatropin, marketed as SKYTROFA)- SKYTROFA revenue for the second quarter of 2025 totaled EUR50.7 million, including a negative foreign currency impact of EUR1.8 million compared to the previous quarter.
- SKYTROFA approved by FDA for the replacement of endogenous growth hormone in adults with growth hormone deficiency (GHD).
- During the fourth quarter of 2025, plan to initiate basket trial for several established growth-hormone indications including: Idiopathic Short Stature (ISS), short stature homeobox-containing gene deficiency (SHOX deficiency), Turner syndrome, and Small for Gestational Age (SGA).
- TransCon CNP:
(navepegritide, NDA filed)- FDA accepted for priority review the New Drug Application (NDA) for the treatment of children with achondroplasia, Prescription Drug User Fee Act (PDUFA) goal date of November 30, 2025. Expect to submit Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) during the third quarter of 2025.
- During the fourth quarter of 2025, plan to submit an IND or similar to investigate TransCon CNP alone and in combination with TransCon hGH for the treatment of hypochondroplasia.
- TransCon CNP + TransCon hGH Combination Therapy
(navepegritide plus lonapegsomatropin)- Reported interim topline Week 26 data from COACH, the combination TransCon CNP and TransCon hGH trial. Week 26 data showed improved treatment benefits in children with achondroplasia (ages 2-11 years). Week 52 data expected in the fourth quarter of 2025.
- Initiation of a Phase 3 combination trial expected in the fourth quarter of 2025.
- Oncology Programs
- Clinical development of TransCon IL-2 B/γ continues.
- Financial Update
- As of June 30, 2025, Ascendis Pharma had cash and cash equivalents totaling EUR494 million, compared to EUR560 million as of December 31, 2024.
Second Quarter 2025 Financial Results
Total revenue for the second quarter of 2025 was EUR158.0 million, compared to EUR36.0 million during the same period in 2024. The year-over-year increase in revenue was primarily attributable to an increase in product revenue, which reflected a contribution of EUR97.8 million from YORVIPATH.
| Total Revenue (In EUR'000s) |
Three Months Ended June 30, | Six Months Ended June 30, | |||||
| 2025 | 2024 | 2025 | 2024 | ||||
| Revenue | |||||||
| Commercial products | 153,663 | 31,389 | 249,690 | 97,888 | |||
| Rendering of services and clinical supply | 3,570 | 3,740 | 7,094 | 8,365 | |||
| Licenses | 812 | 869 | 2,214 | 25,639 | |||
| Total revenue | 158,045 | 35,998 | 258,998 | 131,892 | |||
| Commercial Product Revenue (In EUR'000s) |
Three Months Ended June 30, | Six Months Ended June 30, | |||||
| 2025 | 2024 | 2025 | 2024 | ||||
| Revenue from commercial products | |||||||
| SKYTROFA(R) | 50,706 | 26,202 | 102,044 | 91,207 | |||
| YORVIPATH(R) | 102,957 | 5,187 | 147,646 | 6,681 | |||
| Total revenue from commercial products | 153,663 | 31,389 | 249,690 | 97,888 | |||
Research and development costs for the second quarter of 2025 were EUR72.0 million, compared to EUR83.5 million during the same period in 2024. The decrease was driven by the maturity of clinical trials within our growth disorders portfolio.
Selling, general, and administrative expenses for the second quarter of 2025 were EUR107.6 million, compared to EUR74.3 million during the same period in 2024. The increase was primarily due to the continued impact from commercial expansion, including global launch activities for YORVIPATH.
Total operating expenses for the second quarter of 2025 were EUR179.5 million, compared to EUR157.8 million during the same period in 2024.
Net finance income for the second quarter of 2025 was EUR22.0 million, compared to EUR29.4 million during the same period in 2024. The decrease was primarily driven by non-cash items.
For the second quarter of 2025, Ascendis Pharma reported a net loss of EUR38.9 million, or EUR0.64 per share basic and EUR0.82 diluted compared to a net loss of EUR109.4 million, or EUR1.91 per share basic and EUR2.21 diluted for the same period in 2024.
As of June 30, 2025, Ascendis Pharma had cash and cash equivalents totaling EUR494 million compared to EUR560 million as of December 31, 2024. As of June 30, 2025, Ascendis Pharma had 61,151,463 ordinary shares outstanding, including 597,055 ordinary shares represented by ADSs held by the company.
Conference Call and Webcast Information
Ascendis Pharma will host a conference call and webcast today at 4:30 pm Eastern Time (ET) to discuss its second quarter 2025 financial results.
Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at https://investors.ascendispharma.com. A replay of the webcast will be available in this section of the Ascendis Pharma website shortly after the conclusion of the event for 30 days.
About Ascendis Pharma A/S
Ascendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis' future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis' planned MAA submission for TransCon CNP; (ii) the timing and results of clinical trials; (iii) Ascendis' expectations with respect to its revenue base and path to cashflow breakeven; (iv) the potential approval of TransCon CNP as a monotherapy in children with achondroplasia; (v) Ascendis' ability to provide patients with highly differentiated medicines; (vi) the planned label expansions of SKYTROFA; (vii) Ascendis' expectations regarding the PDUFA date for TransCon CNP; (viii) Ascendis' plans to submit IND applications or similar for a basket trial evaluating TransCon hGH in additional indications and to investigate TransCon CNP alone or in combination with TransCon hGH for the treatment of hypochondroplasia; (ix) Ascendis' ability to apply its TransCon technology platform to make a meaningful difference for patients, and (x) Ascendis' application of its TransCon technologies to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers, distributors and service providers for Ascendis' products and product candidates; unforeseen safety or efficacy results in Ascendis' development programs or on-market products; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen expenses related to Ascendis' development programs; unforeseen selling, general and administrative expenses, other research and development expenses and Ascendis' business generally; delays in the development of its programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; Ascendis' ability to obtain additional funding, if needed, to support its business activities; the impact of international economic, political, legal, compliance, social and business factors, including tariffs and trade policies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis' business in general, see Ascendis' Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 12, 2025, and Ascendis' other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.
Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon, SKYTROFA(R), and YORVIPATH(R) are trademarks owned by the Ascendis Pharma group.
(C) August 2025 Ascendis Pharma A/S.
| Investor Contacts: | Media Contact: |
| Sarada Weerasinghe | Melinda Baker |
| Ascendis Pharma | Ascendis Pharma |
| ir@ascendispharma.com | media@ascendispharma.com |
| Patti Bank | |
| ICR Healthcare | |
| +1 (415) 513-1284 | |
| patti.bank@icrhealthcare.com | |
FINANCIAL TABLES FOLLOW
| Ascendis Pharma A/S Consolidated Statements of Profit or (Loss) and Comprehensive Income / (Loss) (In EUR'000s, except per share data) |
Three Months Ended June 30, |
Six Months Ended June 30, |
|||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||
| Consolidated Statement of Profit or (Loss) | |||||||||||
| Revenue | 158,045 | 35,998 | 258,998 | 131,892 | |||||||
| Cost of sales | 31,447 | 11,465 | 48,963 | 19,034 | |||||||
| Gross profit | 126,598 | 24,533 | 210,035 | 112,858 | |||||||
| Research and development expenses | 71,988 | 83,478 | 158,591 | 154,165 | |||||||
| Selling, general, and administrative expenses | 107,561 | 74,312 | 208,608 | 141,095 | |||||||
| Operating profit/(loss) | (52,951 | ) | (133,257 | ) | (157,164 | ) | (182,402 | ) | |||
| Share of profit/(loss) of associates | (4,097 | ) | (5,322 | ) | 22,482 | (11,118 | ) | ||||
| Finance income | 55,059 | 49,052 | 83,912 | 14,395 | |||||||
| Finance expenses | 33,018 | 19,624 | 77,803 | 58,553 | |||||||
| Profit/(loss) before tax | (35,007 | ) | (109,151 | ) | (128,573 | ) | (237,678 | ) | |||
| Income taxes (expenses) | (3,848 | ) | (229 | ) | (4,909 | ) | (2,737 | ) | |||
| Net profit/(loss) for the period | (38,855 | ) | (109,380 | ) | (133,482 | ) | (240,415 | ) | |||
| Attributable to owners of the Company | (38,855 | ) | (109,380 | ) | (133,482 | ) | (240,415 | ) | |||
| Basic earnings/(loss) per share | EUR (0.64 | ) | EUR (1.91 | ) | EUR (2.22 | ) | EUR (4.21 | ) | |||
| Diluted earnings/(loss) per share | EUR (0.82 | ) | EUR (2.21 | ) (1) | EUR (2.22 | ) | EUR (4.21 | ) | |||
| (1)Dilutive earnings per share for the three months ended June 30, 2024, has been restated. Refer to Note 6, “Earnings Per Share” for further information. | |||||||||||
| Consolidated Statement of Comprehensive Income or (Loss) | |||||||||||
| Net profit/(loss) for the period | (38,855 | ) | (109,380 | ) | (133,482 | ) | (240,415 | ) | |||
| Other comprehensive income/(loss) | |||||||||||
| Items that may be reclassified subsequently to profit or (loss): | |||||||||||
| Exchange differences on translating foreign operations | (1,399 | ) | 15 | (1,474 | ) | 78 | |||||
| Other comprehensive income/(loss) for the period, net of tax | (1,399 | ) | 15 | (1,474 | ) | 78 | |||||
| Total comprehensive income/(loss) for the period, net of tax | (40,254 | ) | (109,365 | ) | (134,956 | ) | (240,337 | ) | |||
| Attributable to owners of the Company | (40,254 | ) | (109,365 | ) | (134,956 | ) | (240,337 | ) | |||
| Ascendis Pharma A/S Consolidated Statements of Financial Position (In EUR'000s) |
June 30, 2025 | December 31, 2024 | |||
| Assets | |||||
| Non-current assets | |||||
| Intangible assets | 3,790 | 4,028 | |||
| Property, plant and equipment | 93,542 | 98,714 | |||
| Investments in associates | 34,902 | 13,575 | |||
| Other receivables | 2,711 | 2,317 | |||
| 134,945 | 118,634 | ||||
| Current assets | |||||
| Inventories | 303,381 | 295,609 | |||
| Trade receivables | 110,452 | 166,280 | |||
| Income tax receivables | 2,738 | 1,775 | |||
| Other receivables | 8,029 | 9,385 | |||
| Prepayments | 34,311 | 28,269 | |||
| Cash and cash equivalents | 494,046 | 559,543 | |||
| 952,957 | 1,060,861 | ||||
| Total assets | 1,087,902 | 1,179,495 | |||
| Equity and liabilities | |||||
| Equity | |||||
| Share capital | 8,211 | 8,149 | |||
| Distributable equity | (195,783 | ) | (113,855 | ) | |
| Total equity | (187,572 | ) | (105,706 | ) | |
| Non-current liabilities | |||||
| Borrowings | 330,186 | 365,080 | |||
| Contract liabilities | 692 | 5,000 | |||
| Deferred tax liabilities | 9,596 | 7,258 | |||
| 340,474 | 377,338 | ||||
| Current liabilities | |||||
| Convertible notes, matures in April 2028 | |||||
| Borrowings | 418,073 | 458,207 | |||
| Derivative liabilities | 186,579 | 150,670 | |||
| 604,652 | 608,877 | ||||
| Other current liabilities | |||||
| Borrowings | 44,275 | 33,329 | |||
| Contract liabilities | 1,789 | 936 | |||
| Trade payables and accrued expenses | 93,718 | 96,394 | |||
| Other liabilities | 39,924 | 67,956 | |||
| Income tax payables | 711 | 1,222 | |||
| Provisions | 149,931 | 99,149 | |||
| 330,348 | 298,986 | ||||
| 935,000 | 907,863 | ||||
| Total liabilities | 1,275,474 | 1,285,201 | |||
| Total equity and liabilities | 1,087,902 | 1,179,495 | |||
